Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jul 21;14(2):490. doi: 10.4081/oncol.2020.490

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

©Copyright: the Author(s)

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 2. — Indirect comparison between anti-PD1 and anti-PD-L1 exploring possible toxicity differences: A, indirect comparison of led to discontinuation, ≥ grade 3 and all grade toxicity percentages between anti-PD1 and anti-PD-L1 agents in the second- and beyond line treatment of aNSCLC by available phase III randomized trials; B, indirect comparison of immune-related adverse events percentages between anti-PD1 and anti-PD-L1 agents in the second- and beyond line treatment of aNSCLC by available phase III randomized trials. aNSCLC, advanced nonsmall-cell lung cancer; ADCC, antibody-dependent cell-mediated cytotoxicity (ADCC); Atezo, atezolizumab; CM, checkmate; G, grade; KN, keynote; Ig, immunoglobulin; ImP, ImPower; moAbs, monoclonal antibodies; Nivo, nivolumab; ORR, overall response rate; OS, overall survival; PD1, programmed cell death 1; PD-L1, programmed cell death ligand 1; Pembro, pembrolizumab; PFS, progressionfree survival; Sq, squamous.